Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2017 06:50 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results

Q1 Cash Balance of $156.9M – Cash Through Q3 2019 Phase 2 Demcizumab DENALI Non-Small Cell Lung Cancer Trial Did Not Meet Endpoints Focused on Immuno-Oncology Pipeline and Celgene Collaboration...
May 04, 2017 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial

REDWOOD CITY, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer...
May 03, 2017 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017

REDWOOD CITY, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer...
April 24, 2017 16:35 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Workforce Reduction

REDWOOD CITY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
April 17, 2017 08:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints

Company also Announces Discontinuation of Brontictuzumab Phase 1b Study OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results REDWOOD CITY,...
April 10, 2017 08:02 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept

REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
April 10, 2017 08:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed’s Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint

REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
April 05, 2017 08:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017

WASHINGTON and REDWOOD CITY, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...
April 03, 2017 13:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017

WASHINGTON and REDWOOD CITY, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...
March 08, 2017 16:05 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right